Submitted by Anonymous (not verified) on 20 September 2023 - 14:21
Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Arthritis, Rheumatoid;Arthritis, Psoriatic;Spondylitis, Ankylosing;Uveitis;Hidradenitis Suppurativa;Colitis, Ulcerative;Arthritis, Juvenile Rheumatoid;Crohn Disease;Skin Diseases, Papulosquamous, Date of authorisation: 26/07/2018, Revision: 13, Status: Authorised
Source: